NCT06813781View on ClinicalTrials.gov

Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

December 19, 2024

Primary Completion Date

October 2, 2025

Study Completion Date

October 2, 2025

Conditions
Hepatic Impairment
Interventions
DRUG

AZD5004

Dose 1

Trial Locations (5)

32809

Research Site, Orlando

33014

Research Site, Miami Lakes

78215

Research Site, San Antonio

92377

Research Site, Rialto

92630

Research Site, Lake Forest

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
collaborator

Fortrea Clinical Research Unit Inc.

UNKNOWN

lead

AstraZeneca

INDUSTRY